Researchers have made more advancements in multiple sclerosis in the last five years than in the previous 70 years. Knowing ...

In multiple sclerosis (MS), a person's immune system attacks the protective ... DMTs are not used to treat individual relapses or daily MS symptoms. Moderate to severe MS relapses are typically ...

Mikael Simons, MD, a neurologist and researcher at Technical University Munich and the Centre for Neurodegenerative Diseases ...

Migraine may be a symptom of prodromal multiple sclerosis (MS), as the risk for migraine gradually increased closer to the ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...

Formerly believed to predominantly affect Caucasians, new research indicates that MS actually may hit Blacks the hardest.

is the most common type of multiple sclerosis (MS), making up about 85% of diagnoses. RRMS involves periods known as relapses, during which symptoms worsen, followed by periods of symptom ...

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...